OncoMatch/Clinical Trials/NCT07448831
A Phase II Clinical Trial on Neo-adjuvant Pembrolizumab in Patients With pT3b-T4a/b cN0M0 Melanoma.
Is NCT07448831 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies Pembrolizumab for melanoma (skin cancer).
Treatment: Pembrolizumab — This study, called NeoSenti, is exploring whether giving one dose of the immunotherapy drug pembrolizumab before surgery can help the immune system fight melanoma more effectively. The study includes adults with high-risk melanoma who do not show any signs of the cancer having spread on scans. Participants receive a single infusion of pembrolizumab six weeks before their scheduled sentinel lymph node biopsy. The goal is to see if this early treatment can reduce or eliminate tiny cancer cells that might already be in the lymph nodes but are too small to detect. After surgery, patients whose melanoma stage normally requires further treatment will continue with standard immunotherapy for one year. Others will move directly into follow-up care. All participants are monitored closely for five years with regular scans, blood tests, and check-ups to watch for any signs of recurrence and to ensure their safety.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Cancer type
Melanoma
Disease stage
Required: Stage PT1B, PT2A, PT2B, PT3A, PT3B, PT4A, PT4B (AJCC8)
High risk primary melanoma is defined in this study as the following AJCC8 T-stages: * pT1b-3a, with a poor prognostic score on the Merlin™ test ("Merlin™ high risk"); * pT3b-4b, irrespective of their Merlin™ test result
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: checkpoint inhibitor
Patients who have previously been exposed to checkpoint inhibitors
Cannot have received: systemic treatment for melanoma
No prior exposure to systemic treatment for melanoma (adjuvant or curative)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT07448831 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
What disease stage is eligible?
Stage PT1B or PT2A or PT2B or PT3A or PT3B or PT4A or PT4B is required.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages